

## **VIRALEZE™ distribution and supply to Vietnam**

- **Starpharma has received its first orders of approximately 100,000 units of VIRALEZE™ antiviral nasal spray to Vietnam, with product expected to arrive in Vietnam in November**
- **Registration of VIRALEZE™ in Vietnam is already well advanced**
- **Vietnam is experiencing a widespread Delta outbreak with ~20% of its population fully vaccinated**
- **A portion of VIRALEZE™ from these initial orders will be donated to hospitals and healthcare organisations in Vietnam**
- **VIRALEZE™ is a broad-spectrum antiviral nasal spray that contains SPL7013, which has been shown to have potent antiviral and virucidal activity in multiple respiratory viruses, including inactivation of >99.9% of the Delta variant of SARS-CoV-2, in laboratory studies**

**Melbourne, Australia; 26 October 2021: Starpharma** (ASX: SPL, OTCQX: SPHRY) today announced it has signed an initial supply contract for VIRALEZE™ antiviral nasal spray in Vietnam and first delivery into Vietnam is expected in early November. In parallel with completing registration, Starpharma is finalising an ongoing distribution agreement for VIRALEZE™ in Vietnam which will allow subsequent larger orders and ongoing supply.

Vietnam, which has a population of approximately 97 million, is experiencing a significant Delta outbreak with ~20 per cent of its population fully vaccinated<sup>1</sup>. According to figures from the World Health Organisation, the death toll in Vietnam from COVID-19 exceeds 21,000<sup>2</sup>.

Starpharma's initial orders committed for purchase under this initial supply distribution contract for VIRALEZE™ to Vietnam total approximately 100,000 units of VIRALEZE™ with further larger orders expected upon signing of an ongoing distribution agreement, which is currently being finalised. The distribution arrangements for Vietnam include Australian-based HealthCo Australia Pty Ltd (**HealthCo**), with Truong Bao Land International Investment Company Limited (**TBL**) responsible for importation, sales, marketing, and distribution in Vietnam. TBL will also utilise the local medical distribution networks in Vietnam of associated company Nam Thanh Trade and Medical Services Company Limited<sup>3</sup>. The initial supply contract for the first shipments of VIRALEZE™ has a maximum three-month term and will be replaced by an ongoing distribution arrangement, which is currently being finalised. These arrangements are exclusive for retail, pharmacies, clinics, and hospitals in Vietnam.

The first shipment of VIRALEZE™ is expected in Vietnam in early November 2021 and launch preparations for the product are already well advanced with promotions to start shortly. A portion of VIRALEZE™ from these orders will be donated to hospitals and other healthcare organisations in Vietnam.

Under the initial contract, Starpharma will supply VIRALEZE™, with TBL responsible for sales, distribution, and marketing of the product locally in Vietnam. Registration of VIRALEZE™ in Vietnam is already well advanced with full registration expected in the coming weeks following the final listing step.

<sup>1</sup> <https://covidvax.live/location/vnm>

<sup>2</sup> <https://covid19.who.int/region/wpro/country/vn>

<sup>3</sup> [NAM THANH MEDICAL CO., LTD](#) (short name: NAMTHANH MSATCO; Business Registration Certificate No: 0107308573) is a supplier of medical products and equipment, including rapid COVID-19 test kits, based in Vietnam.

Dr Jackie Fairley, Starpharma CEO commented: “We are very pleased to be able to make VIRALEZE™ available to Vietnamese consumers and frontline workers next month, especially given the current Delta outbreak and vaccination rates in Vietnam. This supply contract is one of a number of international commercial arrangements for VIRALEZE™ being negotiated by Starpharma and we look forward to making further announcements about those soon.”

VIRALEZE™ is a broad-spectrum antiviral nasal spray. The antiviral agent in VIRALEZE™, referred to as SPL7013, has been shown to have potent antiviral and virucidal activity in multiple respiratory viruses and multiple variants of SARS-CoV-2, including inactivation of >99.9% of the highly infectious Delta variant, in laboratory studies. VIRALEZE™ is applied in the nose to provide a physical barrier - between viruses and the nasal mucous membrane - that traps and irreversibly inactivates virus.

VIRALEZE™ is registered in Europe and India, and available online in certain markets. VIRALEZE™ is partnered with LloydsPharmacy in the UK, ADMENTA Italia Group in Italy, and Starpharma is in advanced discussions with potential commercial partners elsewhere in Europe, Asia, India, and other regions. VIRALEZE™ is not registered for sale or supply in Australia.

#### **VIRALEZE™ Antiviral Nasal Spray**

VIRALEZE™ contains SPL7013, which has been shown in laboratory studies to inactivate a broad spectrum of respiratory/cold viruses, including multiple SARS-CoV-2 variants, influenza, and RSV. VIRALEZE™ is registered for sale in Europe and India. VIRALEZE™ is not registered for sale or supply in Australia.

SPL7013 is also included in other products registered in >45 countries and available for sale in the UK, Europe, Japan, South East Asia, Australia and New Zealand.

*Starpharma acknowledges the \$1 million in funding for the development of VIRALEZE™ provided by the Australian Government’s Medical Research Future Fund (MRFF) Biomedical Translation Bridge (BTB) Program, with support from UniQuest. Delivered by MTPConnect, the Australian Government’s BTB program is a \$22.3 million MRFF initiative that provides up to \$1 million in matched funding to nurture the translation of new therapies, technologies and medical devices through to proof of concept to turn innovative medical ideas into reality.*

---

#### **About Starpharma**

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHY) is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for respiratory viruses, DEP® drug delivery and VivaGel®. Starpharma has developed VIRALEZE™, an antiviral nasal spray that is registered for sale in the UK/Europe and India, and available in certain markets online. VIRALEZE™ is not approved for sale or supply in Australia. SPL7013 is utilised in approved products - the VivaGel® condom and VivaGel® BV. VivaGel® BV has been licensed in >160 countries, is registered in >45 countries and available for sale in the UK, Europe, Japan, South East Asia, South Africa, Australia and New Zealand.

As a leading company in dendrimer-based drug delivery, Starpharma’s proprietary drug delivery platform technology, DEP®, is being used to improve pharmaceuticals, to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP® versions of existing drugs, particularly in the area of anti-cancer therapies. DEP® partnerships include oncology programs with AstraZeneca, with Merck in the area of Antibody Drug Conjugates (ADCs), with Chase Sun in the area of anti-infectives and other world leading pharmaceutical companies. Starpharma’s partnered DEP® programs have the potential to generate significant future milestones and royalties.

[Starpharma.com](http://Starpharma.com) | [Twitter](https://twitter.com/Starpharma) | [LinkedIn](https://www.linkedin.com/company/starpharma)

---

#### **Media: Sumit Media**

Grant Titmus  
Mob: +61 419 388 161  
[grant@sumitmedia.com.au](mailto:grant@sumitmedia.com.au)

#### **Starpharma Holdings Limited**

Dr Jackie Fairley, Chief Executive Officer  
Nigel Baade, CFO and Company Secretary  
+61 3 8532 2704  
[investor.relations@starpharma.com](mailto:investor.relations@starpharma.com)  
4-6 Southampton Crescent  
Abbotsford Vic 3067

#### **Disclosure**

This ASX Announcement was authorised for release by the Chairman, Mr Rob Thomas.

**Forward Looking Statements**

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.